期刊
DERMATITIS
卷 32, 期 6, 页码 365-374出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/DER.0000000000000726
关键词
-
类别
This systematic review summarized patch testing results in patients receiving immunosuppressive therapy, showing that most dermatitis patients maintained positive reactions to specific allergens even while on immunosuppressants, indicating a correlation between immunosuppressants and positive patch test results.
Patch testing, used in the assessment of allergic contact dermatitis, is ideally avoided in patients receiving immunosuppressive therapy because of concerns with reductions in accuracy; however, this is not well characterized in the literature. This systematic review summarizes patch testing results in patients receiving immunosuppressive therapy. We identified 16 studies, comprising 195 patients with dermatitis or psoriasis, who were patch tested while receiving immunosuppressants. Of these, 7 studies, comprising 85 patients with dermatitis, patch tests were performed before and during immunosuppression. Overall, 67.9% (n = 19) of the dermatitis patients receiving dupilumab maintained positive reactions to an allergen that previously graded as a 2+/3+ reaction. Several immunosuppressants were also associated with positive patch test results for various allergens. These include dupilumab, cyclosporine, and low-dose prednisone (<= 10 mg/d) for dermatitis, and tumor necrosis factor alpha inhibitors, ustekinumab, and methotrexate for psoriasis. Ideally, it is preferable to patch test when patients are not receiving oral immunosuppressants or immunomodulators. However, clinicians may choose to assess the risks and benefits of patch testing for each patient given the impact of allergic contact dermatitis on patient quality of life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据